Journal article
Shasha Yin, Charles Brobbey, Lauren E. Ball, Tianmin Fu, Daniel J. Sprague, Wenjian Gan
Science Advances, 2025
Science Advances, 2025
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Yin, S., Brobbey, C., Ball, L. E., Fu, T., Sprague, D. J., & Gan, W. (2025). BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling. Science Advances.
Chicago/Turabian
Click to copy
Yin, Shasha, Charles Brobbey, Lauren E. Ball, Tianmin Fu, Daniel J. Sprague, and Wenjian Gan. “BRD9 Functions as a Methylarginine Reader to Regulate AKT-EZH2 Signaling.” Science Advances (2025).
MLA
Click to copy
Yin, Shasha, et al. “BRD9 Functions as a Methylarginine Reader to Regulate AKT-EZH2 Signaling.” Science Advances, 2025.
BibTeX Click to copy
@article{shasha2025a,
title = {BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling},
year = {2025},
journal = {Science Advances},
author = {Yin, Shasha and Brobbey, Charles and Ball, Lauren E. and Fu, Tianmin and Sprague, Daniel J. and Gan, Wenjian}
}
Abstract
Recognition of methylarginine marks by effector proteins (“readers”) is a critical link between arginine methylation and various cellular processes. Recently, we identified methylation of AKT1 at arginine-391 (R391), but the reader for this methylation has yet to be characterized. Here, we show that bromodomain-containing protein 9 (BRD9), a reader of acetylated lysine, unexpectedly recognizes methylated R391 of AKT1 through an aromatic cage in its bromodomain. Disrupting the methylarginine reader function of BRD9 suppresses AKT activation and tumorigenesis. RNA sequencing data show that BRD9 and AKT coregulate a hallmark transcriptional program in part through enhancer of zeste homolog 2 (EZH2)–mediated methylation of histone-3 lysine-27. We also find that inhibitors of BRD9 and EZH2 display synergistic effects on suppression of cell proliferation and tumor growth. Collectively, our study reveals a previously unknown function of BRD9 and a potential therapeutic strategy for cancer treatment by combining BRD9 and EZH2 inhibitors.